Atorvastatin normalizes endothelial function in healthy smokers

Area of Science:

• Cardiovascular Medicine
• Pharmacology
• Endothelial Biology

Background:

• Endothelial dysfunction is a predictor of cardiovascular disease.
• Smokers often exhibit impaired endothelial function, even with normal lipid profiles.
• Statins are primarily known for lipid-lowering effects but may have pleiotropic vascular benefits.

Purpose of the Study:

• To investigate the effect of atorvastatin on endothelial function in smokers with normal cholesterol.
• To compare atorvastatin's impact on endothelial function between smokers and non-smokers.
• To determine if improvements in endothelial function are linked to LDL cholesterol reduction.

Main Methods:

• Open-label, randomized cross-over study involving 20 healthy smokers and 20 non-smokers.
• Participants received either 80 mg of atorvastatin or placebo.
• Endothelial function was assessed using flow-mediated dilation (FMD) measurements.

Main Results:

• Smokers had significantly lower baseline FMD compared to non-smokers (2.2% vs. 4.5%, P<0.05).
• Atorvastatin treatment increased FMD in smokers (to 4.0%, P<0.05), with levels returning to baseline during placebo.
• Atorvastatin had no significant effect on FMD in non-smokers, and changes in FMD were not correlated with LDL cholesterol reduction.

Conclusions:

• High-dose atorvastatin (80 mg) can improve endothelial function in smokers with normal lipid levels.
• The beneficial effect of atorvastatin on endothelial function in smokers is independent of its LDL-lowering capacity.
• Statin therapy may represent a therapeutic strategy to mitigate endothelial dysfunction associated with smoking.